分子检测技术的不断进步极大地推动了肺癌精准医学的发展,但是肿瘤的异质性与肿瘤的转移、复发和耐药密切相关,并且具有同一基因突变的不同肺癌患者采用不同的治疗策略会呈现出一定的疗效差异,因此现代精准医学的发展亟需通过个性化的...分子检测技术的不断进步极大地推动了肺癌精准医学的发展,但是肿瘤的异质性与肿瘤的转移、复发和耐药密切相关,并且具有同一基因突变的不同肺癌患者采用不同的治疗策略会呈现出一定的疗效差异,因此现代精准医学的发展亟需通过个性化的肿瘤模型来精准制定个性化的治疗策略。肺癌类器官(lung cancer organoid,LCO)能够高度模拟肿瘤在体内的生物学特征,促进抗体药物偶联物等创新药物在肺癌精准医学的应用。随着LCO与肿瘤微环境共培养模型和微流控芯片等组织工程技术的发展,LCO可以更好地保留肿瘤组织的生物学特征和功能,进一步提高高通量和自动化药物敏感性实验。本文结合了最新的LCO研究进展,总结了LCO在肺癌精准医学中的应用进展与挑战。展开更多
Parkinson’s disease(PD)is a common neurodegenerative disorder with profound impact on patients’quality of life and long-term health,and early detection and intervention are particularly critical.In recent years,the ...Parkinson’s disease(PD)is a common neurodegenerative disorder with profound impact on patients’quality of life and long-term health,and early detection and intervention are particularly critical.In recent years,the search for precise and reliable biomarkers has become one of the key strategies to effectively address the clinical challenges of PD.In this paper,we systematically evaluated potential biomarkers,including proteins,metabolites,epigenetic markers,and exosomes,in the peripheral blood of PD patients.Protein markers are one of the main directions of biomarker research in PD.In particular,α‑synuclein and its phosphorylated form play a key role in the pathological process of PD.It has been shown that aggregation ofα-synuclein may be associated with pathologic protein deposition in PD and may be a potential marker for early diagnosis of PD.In terms of metabolites,uric acid,as a metabolite,plays an important role in oxidative stress and neuroprotection in PD.It has been found that changes in uric acid levels may be associated with the onset and progression of PD,showing its potential as an early diagnostic marker.Epigenetic markers,such as DNA methylation modifications and miRNAs,have also attracted much attention in Parkinson’s disease research.Changes in these markers may affect the expression of PD-related genes and have an important impact on the onset and progression of the disease,providing new research perspectives for the early diagnosis of PD.In addition,exosomes,as a potential biomarker carrier for PD,are able to carry a variety of biomolecules involved in intercellular communication and pathological regulation.Studies have shown that exosomes may play an important role in the pathogenesis of PD,and their detection in blood may provide a new breakthrough for early diagnosis.It has been shown that exosomes may play an important role in the pathogenesis of PD,and their detection in blood may provide new breakthroughs in early diagnosis.In summary,through in-depth evaluation of biomarkers in the peripheral blood of PD patients,this paper demonstrates the important potential of these markers in the early diagnosis of PD and in the study of pathological mechanisms.Future studies will continue to explore the clinical application value of these biomarkers to promote the early detection of PD and individualized treatment strategies.展开更多
文摘分子检测技术的不断进步极大地推动了肺癌精准医学的发展,但是肿瘤的异质性与肿瘤的转移、复发和耐药密切相关,并且具有同一基因突变的不同肺癌患者采用不同的治疗策略会呈现出一定的疗效差异,因此现代精准医学的发展亟需通过个性化的肿瘤模型来精准制定个性化的治疗策略。肺癌类器官(lung cancer organoid,LCO)能够高度模拟肿瘤在体内的生物学特征,促进抗体药物偶联物等创新药物在肺癌精准医学的应用。随着LCO与肿瘤微环境共培养模型和微流控芯片等组织工程技术的发展,LCO可以更好地保留肿瘤组织的生物学特征和功能,进一步提高高通量和自动化药物敏感性实验。本文结合了最新的LCO研究进展,总结了LCO在肺癌精准医学中的应用进展与挑战。
文摘Parkinson’s disease(PD)is a common neurodegenerative disorder with profound impact on patients’quality of life and long-term health,and early detection and intervention are particularly critical.In recent years,the search for precise and reliable biomarkers has become one of the key strategies to effectively address the clinical challenges of PD.In this paper,we systematically evaluated potential biomarkers,including proteins,metabolites,epigenetic markers,and exosomes,in the peripheral blood of PD patients.Protein markers are one of the main directions of biomarker research in PD.In particular,α‑synuclein and its phosphorylated form play a key role in the pathological process of PD.It has been shown that aggregation ofα-synuclein may be associated with pathologic protein deposition in PD and may be a potential marker for early diagnosis of PD.In terms of metabolites,uric acid,as a metabolite,plays an important role in oxidative stress and neuroprotection in PD.It has been found that changes in uric acid levels may be associated with the onset and progression of PD,showing its potential as an early diagnostic marker.Epigenetic markers,such as DNA methylation modifications and miRNAs,have also attracted much attention in Parkinson’s disease research.Changes in these markers may affect the expression of PD-related genes and have an important impact on the onset and progression of the disease,providing new research perspectives for the early diagnosis of PD.In addition,exosomes,as a potential biomarker carrier for PD,are able to carry a variety of biomolecules involved in intercellular communication and pathological regulation.Studies have shown that exosomes may play an important role in the pathogenesis of PD,and their detection in blood may provide a new breakthrough for early diagnosis.It has been shown that exosomes may play an important role in the pathogenesis of PD,and their detection in blood may provide new breakthroughs in early diagnosis.In summary,through in-depth evaluation of biomarkers in the peripheral blood of PD patients,this paper demonstrates the important potential of these markers in the early diagnosis of PD and in the study of pathological mechanisms.Future studies will continue to explore the clinical application value of these biomarkers to promote the early detection of PD and individualized treatment strategies.
